Investors and Partners

> Investors

Tailwind Capital

Tailwind Capital is a leading private equity firm investing in growth-oriented middle market companies in the health care, business services, and media/communications sectors. Tailwind partners with management teams to build businesses through organic growth, strategic acquisition, and operational improvement. The firm currently has over $1 billion under management. Representative Tailwind investments include VersaPharm (generic pharmaceuticals), Aircast (orthopedic devices), Freedom Innovations (prosthetic devices), SDI Health (health care analytics), TowerCo (wireless infrastructure), Archway (marketing logistics), and Trover Solutions (insurance services). For more information about Tailwind, please visit

Galen Partners

Galen Partners is a leading health care private equity investment firm based in Stamford, Connecticut. The firm focuses on growth equity investments in healthcare technology enabled services, medical devices, and specialty pharmaceutical companies. With nearly $1 billion under management raised through five funds, Galen has invested in more than 70 companies since 1990. Galen’s specialty pharmaceutical investments include Acura Pharmaceuticals, Dow Pharmaceutical Sciences (acquired by Valeant Pharmaceuticals in 2008), JDS Pharmaceuticals (acquired by Noven Pharmaceuticals in 2007), and Taro Pharmaceuticals. The firm continues a tradition of strategic collaboration and partnership with its portfolio company management teams to build healthcare market leaders. For more information, please visit Galen’s website at

> Partners

Applied Pharma Research

APR Applied Pharma Research SA is an independent, international, vertically-integrated drug delivery and drug development company in healthcare with registered offices in Switzerland and the United States. It is focused in the research and development of innovative and patented drug delivery systems as well as innovative pharmaceutical products used primarily for oral and topical administration. The APR products and technologies are licensed to third parties for distribution and marketing activities. Research and development activities are carried out directly or under contract. APR has signed licensing agreements with pharmaceutical companies in 117 countries worldwide and its sales are almost totally achieved abroad. For more information about APR, please visit


Leave a Reply

Required fields are marked *.

Keep up to date with everything Nautilus.

We like to be intimately engaged with our customers. Sign up for our newsletter here.